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A B S T R A C T
In 1994 a decision analysis, based on the literature and utility ratings for outcome by a panel of experienced
head and neck physicians, was presented which showed a threshold probability of occult metastases of 20% to
recommend elective treatment of the neck. It was stated that recommendations for the management of the cN0
neck are not immutable and should be reconﬁgured to determine the optimal management based on diﬀerent
sets of underlying assumptions. Although much has changed and is published in the almost 25 years after its
publication, up to date this ﬁgure is still mentioned in the context of decisions on treatment of the clinically
negative (cN0) neck. Therefore, we critically reviewed the developments in diagnostics and therapy and mod-
eling approaches in the context of decisions on treatment of the cN0 neck. However, the results of studies on
treatment of the cN0 neck cannot be translated to other settings due to signiﬁcant diﬀerences in relevant
variables such as population, culture, diagnostic work-up, follow-up, costs, institutional preferences and other
factors. Moreover, patients may have personal preferences and may weigh oncologic outcomes versus morbidity
and quality of life diﬀerently. Therefore, instead of trying to establish “the” best strategy for the cN0 neck or
“the” optimal cut-oﬀ point for elective neck treatment, the approach to optimize the management of the cN0
neck would be to develop and implement models and decision support systems that can serve to optimize choices
depending on individual, institutional, population and other relevant variables.
Introduction
Oral squamous cell carcinomas (OSCC) have a proclivity to metas-
tasize through lymphatics to regional lymph nodes ﬁrst rather than to
spread hematogeneously. Therefore, management of the neck has to be
included in the treatment planning in most of the patients with OSCC.
Moreover, the presence of clinically apparent cervical lymph node
metastases is one of the most important prognostic factors in OSCC
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since it roughly reduces survival by half. Whereas in the treatment of
the overt metastatic lymph nodes in the neck there may be debate on
how best to treat the neck [1], the management of clinically negative
(cN0) neck remains a much more controversial issue. There is general
agreement that elective treatment of the neck is indicated when there is
a high likelihood of occult, clinically undetectable, lymph node me-
tastases, when the neck needs to be entered for surgical treatment of the
primary tumor, or when the patient will be unavailable for regular
follow-up. When there is lower likelihood of occult lymph node me-
tastases, the choice is between elective treatment and watchful waiting.
This question certainly arises in the smaller (T1 and T2) OSCCs, because
these tumors usually can be excised transorally and the neck is not
entered surgically. The dilemma of elective treatment or watchful
waiting was addressed by Lefebvre et al. where they found no clear
advantages of an elective neck dissection (END) in a series of 579 pa-
tients treated for early stage oral cancer between 1974 and 1983 [2].
The rationale for elective treatment is based on the premise that
occult metastases will inevitably progress into clinically manifest dis-
ease and that treatment at an earlier N-stage implies better oncological
outcome [3]. The main arguments against elective treatment of the
neck are that a large proportion of patients are subjected to treatment
that they do not need and elective dissection of the neck is associated
with morbidity, i.e. shoulder morbidity.
However, the question remains, as to which patients should undergo
elective neck dissection and who should not. To answer this question,
the paper of Weiss et al. [4] has been referred to numerous times since
its publication in 1994. The decision analysis in this study concluded
that if the probability of occult metastasis in the neck is greater than
20%, elective treatment of the neck is warranted [4]. Although much
has changed and is published in almost 25 years after its publication,
this ﬁgure is still mentioned in the context of decisions on treatment of
the cN0 neck. Therefore, we critically reviewed the developments in
diagnostics and therapy and modeling approaches in the context of
decisions on treatment of the cN0 neck in OSCC patients.
Decision analyses
Decision analysis is a method by which the eﬀect of diﬀerent vari-
ables concerning the outcome of a treatment can be rigorously ana-
lyzed. Choices of treatments and probabilities of various outcomes are
arranged in a decision tree with the intent of identifying the probability
of certain results given the decision options available. In 1990
Velanovich [5] was probably the ﬁrst to perform a decision analysis for
treatment of head and neck squamous cell carcinoma (HNSCC). The
quality-adjusted life expectancies were determined using best estimates
of survival, recurrence, short-term morbidity and quality of life after
radiotherapy and surgical resection of stage I ﬂoor of mouth cancer
from available literature at that time. The quality-adjusted life ex-
pectancies for surgical resection with neck dissection (18.50 years) was
higher than for surgical resection without neck dissection (14.48 years)
and that for primary radiotherapy (7.95 years). However, sensitivity
analysis showed that these results varied with quality of life assump-
tions and survival data. Therefore, it was recommended that each in-
stitution needs to review its survival data and question patients about
quality of life to determine how treatment options ﬁt into the decision
analysis [5].
Weiss et al. [4] reported in 1994 on the use of decision analysis to
determine the optimal strategy for neck treatment as a function of the
probability of occult cervical lymph node metastasis. To determine the
optimal threshold for treatment, they constructed a decision tree with
the use of a computer model to compare the three major strategies in
the treatment of HNSCC patients with a cN0 neck: END, elective neck
irradiation and observation. Probabilities of each of the possible events
depicted in the trees were gleaned from the available literature at that
time and inserted into the tree structure. Then a sensitivity analysis on
the variable of the probability of occult metastasis was performed to
determine the optimal threshold for treatment of the neck. They con-
cluded that a HNSCC patient with a cN0 neck should be observed if the
probability of occult lymph node metastasis is less than 20%. If the
probability is greater than 20%, treatment of the neck (either END or
elective radiation therapy) is warranted. In the introduction of their
article they state that suggested thresholds in the past were problematic
because they were intuitive, but also because several factors had
changed at the time of their analysis. They mentioned that modern
imaging techniques staged the neck more accurately than ever before
and the likelihood and severity of morbidity associated with neck dis-
section was considerably less as modiﬁed radical neck dissection was
performed at that time instead of the classical radical neck dissection.
Since their study, the means to more accurately assess the status of the
neck have improved considerably (e.g. better imaging and sentinel node
biopsy procedure) and selective END has been popularized based on the
patterns of metastasis. This was also pointed out by Weiss et al. [4]
stating that the conclusions of the analysis are only as good as the data
that are fed into the model. Data that were used in the analysis were
probability of recurrence, successful salvage rate and quality of life
outcome. Salvage therapy was expected to be successful in only 50% of
the patients in the observation group, in whom metastatic lymph nodes
appear in the neck at a later time. However, it can be anticipated that
improved follow-up strategies, e.g. watchful waiting and wait and scan,
will increase the success rate of salvage neck dissections. In their study
the utility (desirability) ratings for outcome were established by a panel
of three experienced head and neck physicians and use of the time trade
oﬀmethod in which the question should be answered how much time of
life one would give up to have a better function (quality of life). It was
argued that patients had diﬃculties in separating out the morbidity of
neck treatment from treatment morbidity in general [4]. However,
patient’s preferences may diﬀer from expectations of treating physi-
cians.
Others [6–9] have also performed studies on decision analysis for
the management of the cN0 neck Using diﬀerent probability assump-
tions of occult lymph node disease, recurrence rate, salvage rate sur-
vival and morbidities (shoulder disability and scar), recommendations
vary from the END for all patients, thresholds of 20–44.4% to perform
END, to careful observation for all patients (Table 1). Methods to per-
form decision analysis have improved. Former studies used a determi-
nistic approach where probabilities are ﬁxed in the model. These stu-
dies, did not consider the expected variations in probabilities and
outcomes that commonly occurs in medical practice. Recent methodo-
logical improvements such as probabilistic approach and discrete event
simulation, where distributions of probabilities are used, are more
realistic. These new models, more than establish a threshold, describe a
cloud of points in a decision quadrant and deﬁne a spectrum of values
where each therapeutic strategy can be chosen.
In fact, as also Weiss et al. [4] stated, recommendations for the
management of the cN0 neck are not immutable and should be re-
conﬁgured to determine the optimal management based on diﬀerent
sets of underlying assumptions. Pitman [10] recommended in 2000 to
lower the threshold to perform END from 20% to 15%, because of the
risk-beneﬁt ratio has changed. However, no decision analysis was
performed. In the present paper we will discuss the diﬀerent factors
which may aﬀect the threshold for performing an END.
Imaging workup for cN0 determination
When reviewing the literature on the management of the cN0 neck
it is important to realize that the staging of the cN0 neck has not been
uniformly done, since diﬀerent diagnostic techniques have been used in
diﬀerent studies. Thus the reported risk of occult metastases is depen-
dent on the diagnostic techniques used. Modern imaging techniques,
such as computed tomography (CT), magnetic resonance imaging
(MRI), positron emission tomography (PET) and ultrasound are more
reliable than palpation. However, these techniques do not detect
R. de Bree et al. Oral Oncology 90 (2019) 87–93
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micrometastases [11]. In a meta-analysis of 73 articles comparing dif-
ferent imaging modalities for the detection of lymph node metastasis in
HNSCC patients with a cN0 neck on palpation for CT, MRI, PET, ul-
trasound and ultrasound-guided ﬁne-needle aspiration (USgFNAC),
pooled estimates for sensitivity of 47.0%, 56.6%, 48.3%, 63.3% and
56.4% were found, respectively. The speciﬁcity for these imaging
techniques was 88.9%, 82.5%, 86.2%, 79.1% and 100%, respectively
[12]. A recent study on FDG-PET/CT in cN0 OSCC patients revealed for
the detection of occult lymph node metastasis a sensitivity of 21.4% and
a speciﬁcity 98.4%. With a low overall rate of occult metastasis a ne-
gative predictive value of 99.1% was reported [13]. A study in 49 or-
opharyngeal squamous cell carcinoma patients with a palpably negative
neck showed that the addition of PET-CT to CT/MRI did not provide
better diagnostic accuracy for detecting nodal metastasis: on a level-by-
level analysis a sensitivity of PET-CT, CT/MRI, and a combination of
PET-CT and CT/MRI of 54.6%, 54.6%, and 60.6%, respectively [14].
USgFNAC was reported to be superior to other imaging techniques,
with reported sensitivity of up to 73% and a speciﬁcity approaching
100% [15]. However, the accuracy is very dependent on the experience
of the sonographer [16] and has been reported to be much lower in a
multicenter clinical setting [17].
In an attempt to improve the detection of occult lymph node me-
tastases the sentinel lymph node (SLN) concept was introduced in early
oral cancer [18]. The most recent meta-analyses showed a pooled
sensitivity of 87–92% and a negative predictive value of 94–96% for the
detection of occult lymph node metastases by SLN biopsy in early oral
squamous cell carcinoma [19,20]. Using SLN biopsy in these patients
the risk of occult lymph node metastases was 4–6%, which is far below
the thresholds to perform an elective neck dissection found in afore-
mentioned decision analyses [4,8].
Predictors for occult nodal involvement in cN0 neck
Prediction proﬁles may be useful in clinical decision making on
treatment of the cN0 neck. If the risk of occult metastases can be as-
sessed reliably, personalized cancer treatment can improve. Depth of
invasion (DOI) of the primary tumor is the most promising pathological
predictive factor for nodal metastases [21,22]. However, the two recent
meta-analyses on this topic involved diﬀerent study groups, measure-
ment techniques and cut-oﬀ values, which hampers good comparison
between studies. Both studies found a wide range for cut-oﬀ values of
1.5–10mm, with a most optimal cut-oﬀ value of 4mm in the meta-
analysis of Huang et al. [22]. Brockhoﬀ et al. [23] found diﬀerent DOI
cut-oﬀ values for a 20% or greater risk of having nodal metastasis in
diﬀerent tumor locations. They suggested to oﬀer a neck dissection in
case of> 2mm DOI in tongue tumors,> 2–3mm DOI in ﬂoor of mouth
tumors and> 3–4mm DOI for the retromolar trigone and alveolus/
hard palate tumors [23]. A recent large study of Liu et al. [24] using a
cut-oﬀ value of 4mm DOI reported poor sensitivity, speciﬁcity, and
positive and negative predictive values for prediction of nodal metas-
tasis (54.2%, 67.3%, 45.0%, and 74.8%, respectively) [24]. Similarly,
in a recent study, Goerkem et al. [25] were not able to ﬁnd an optimal
cut-oﬀ value and reported an area under the curve of 0.54 in an ROC
analysis. They concluded that DOI should not be used to decide on
elective treatment of the neck [25]. The recent publication of the ran-
domized controlled trial on elective neck dissection versus watchful
waiting by D́Cruz et al. [24] deﬁned a threshold for END of 3mm. Using
this threshold the rate of lymph node metastases was 28% in their series
[26]. As a consequence, if all patients with a DOI larger than this would
undergo an END 72% of patients would receive an unnecessary treat-
ment. With the introduction of DOI in the 8th TNM staging system there
is probably some reduction in occult lymph node metastasis for cT1-
2N0 OSCC as compared to the 7th edition of the TNM staging system.
Another option to overcome the clinical dilemma whether or not to
treat a cN0 neck without invasive diagnostic techniques is tumor pro-
ﬁling with biomarkers. Biomarkers may supply additional informationTa
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on the metastatic potential of a tumor. Through the years numerous
biomarkers have been studied and identiﬁed as potentially relevant for
the prediction of regional metastasis. However, due to the complexity of
the metastatic process it is unlikely that a single marker for metastasis
can be identiﬁed. Therefore, techniques allowing the study of many
factors simultaneously seem to be the most promising [27]. In 2005, the
ﬁrst gene expression proﬁle to predict nodal metastasis was developed
and recently validated in a Dutch multicenter study with a negative
predictive value of 89%. Although this seems to be a ﬁgure that has not
been surpassed by other validated proﬁles, its use in clinical practice is
currently still not considered cost-eﬀective [28,29]. Nevertheless, a
combination of both tumor proﬁling and SLN biopsy could further
improve the diagnostic accuracy of staging the neck with limited in-
vasive diagnostic techniques [30].
Follow-up
If cN0 neck is not treated electively a wait and see policy with close
follow-up with or without diagnostic techniques such as USgFNAC is an
option in carefully selected patients. Using such a wait and scan ap-
proach salvage rates of 75–100% have been reported [16,31–33]. These
salvage rates are higher than the salvage rate of 73%, mentioned in the
previously discussed decision analysis of Song et al. as a threshold to
perform an END [8]. Thus, in such strategies futile END can be avoided
in the majority of patients and neck disease control and survival did not
seem to be compromised [34]. However, in the few patients who need a
(salvage) neck dissection for delayed metastases, treatment of the neck
will probably be more extensive, e.g. modiﬁed radical neck dissection
with or without (chemo-)radiotherapy as compared to upfront elective
treatment, by a selective END followed by (chemo-)radiotherapy based
on indication from pathology reports [33].
Morbidity
It is well established that neck dissection is associated with esthetic
(scar) and functional (shoulder) morbidity. This morbidity is char-
acterized by shoulder pain, limitations of abduction and scapular
winging. Shoulder function is an important aspect of health-related
quality of life as it is related to various activities of daily living [35].
Therefore it is an important factor in the considerations whether or not
to treat the neck electively. Modiﬁcations of the radical neck dissection
were fashioned to limit the extent and frequency of shoulder dysfunc-
tion [36]. Eventually, the concept of selective neck dissection (SND)
evolved as a strategy to remove lymph node groups at greatest risk, but
was also intended to reduce morbidity [37]. Spinal accessory nerve
sparing neck dissections are associated with better preservation of
shoulder function as compared to nerve-sacriﬁcing neck dissections.
Nevertheless, signiﬁcant shoulder dysfunction continues to arise, in a
fair number of patients, even when the spinal accessory nerve is spared
during the neck dissection procedure [38,39]. A recent systematic re-
view indeed showed that the prevalence and incidence of shoulder and
neck dysfunction varies by type of neck dissection. Prevalence rates of
pain after (modiﬁed) radical neck dissection (0–100%) were markedly
higher compared to SND (9–25%). Reduction in shoulder abduction
was reported in 92–100% of radical neck dissections, in 23% of mod-
iﬁed radical neck dissections and in 5% of SNDs [40]. Furthermore,
considering the low risk of sublevel IIB lymph node metastasis, this
level can be spared in END and a signiﬁcant reduction on the morbidity
can be expected [41,42]. Giordano et al. [43] reported a higher impact
on the motor action potentials of the spinal accessory nerve in SND
including sublevel IIB compared to patients in whom only sublevel IIA
was dissected [43]. Nevertheless, despite the use of nerve-sparing sur-
gical techniques during neck dissections, the rate of postoperative pa-
ralysis of the trapezius muscle is still high because in almost 40% of the
patients an active motor branch from the cervical plexus is distributed
to all functional parts of the trapezius muscle [44]. The evolution of the
concept for more limited surgery as with SND may impact the clinical
decision making paradigm on whether or not to electively treat the
neck.
Although shoulder morbidity is probably the most important se-
quelae of an END, other morbidities may also appear. Impairment in the
sensitivity of the neck, ear and supraclavicular area is a common
complaint of patients. As expected, early oral cancer patients who un-
derwent SLN biopsy experienced signiﬁcantly less impairment from
cervical scars, and had less sensory dysfunction as compared to patients
who underwent selective END [45]. In modern times, esthetic con-
siderations are also important in the decision making of END. Potential
injury of the marginal branch of the facial nerve is expected in 4–7% of
cases [46]. The scar after dissection can be a reason of concern in some
patients although with the application of minimally invasive surgery in
the neck, these concerns can be surpassed [47].
Costs
Strategies in which not all patients undergo a neck dissection may
save costs. However, before implementing such a strategy it must be
clear that the oncological results are similar. Acevedo et al. [48] per-
formed cost-eﬀectiveness analysis of END in the initial surgical man-
agement of early-stage OSCC using a Markov model to simulate pri-
mary, adjuvant, and salvage therapy, disease recurrence, and survival
in patients with cN0 early stage OSCC patients. They concluded that
compared to watchful waiting of the neck, END reduces costs ($6,000)
and improves health outcomes (0.42 QALYs), making this a cost-ef-
fective treatment strategy for patients with early stage OSCC [48].
Kosuda et al. [49] designed a decision tree sensitivity analysis based on
the two competing strategies: ipsilateral (not further speciﬁed) END
versus SLN biopsy. They found that the introduction of SLN biopsy
instead of ipsilateral END would yield cost savings of $1218 per cN0
classiﬁed patient in Japan and avoid 7 surgical deaths per 1000 patients
who would undergo END [49]. Using a treatment model derived from
data of the European Sentinel Node Trial (SENT), O’Conner et al. [50]
produced estimates of relative treatment costs between patients man-
aged through a traditional selective END or SNLB pathway for units
from Spain, United Kingdom and The Netherlands. The SLN biopsy
pathway appears to be cheaper relative to the traditional selective END
approach in all centers [50]. In the Netherlands, Govers et al. [51]
performed a cost-eﬀectiveness study on the management of the cN0
neck in early stage OSCC. In a decision analytic model the cost-eﬀec-
tiveness was evaluated for selective END, watchful waiting, gene ex-
pression proﬁling followed by neck dissection or watchful waiting, SLN
biopsy followed by neck dissection or watchful waiting, and gene ex-
pression proﬁling and SLN biopsy (for positive gene expression pro-
ﬁling) followed by neck dissection or watchful waiting. SLN biopsy
followed by neck dissection or watchful waiting appeared to be the
most eﬀective and most cost eﬀective strategy. Compared with END the
incremental cost eﬀectiveness ratio was €3356 per quality-adjusted life
year (QALY) gained [51]. Van der Linden et al. [52] calculated the cost-
utility of diﬀerent strategies for the detection of occult lymph node
metastases in cT1-T2N0 OSCC: USgFNAC, SLN biopsy, USgFNAC with if
negative SLN biopsy and selective END. With a 5- or 10-year time
horizon, the SLNB strategy results in the highest number of additional
quality adjusted life years for the smallest additional costs (€56 and
€74, respectively) compared to USgFNAC [52].
Real costs and reimbursements by national reimbursement systems
may vary. Moreover, willingness to pay for a quality adjusted life year
(QALY) may diﬀer from country to country, although no formal
threshold for cost-per-QALY values is yet deﬁned in all countries.
Variations in clinical practice
Variations in clinical practice may result in diﬀerent ways of man-
agement of the cN0 neck. In 2006 a questionnaire on neck management
R. de Bree et al. Oral Oncology 90 (2019) 87–93
90
in case of early oral and oropharyngeal cancer was sent out to all eight
head and neck cancer centers of the Dutch Head and Neck Society [53].
The questionnaire consisted of two parts: the ﬁrst concerning the fac-
tors inﬂuencing the decision of whether or not to perform an END, and
the second concerning case examples (as used previously by Dünne
et al. [54]. This study [53] found, similar to Dünne et al. [54] for
German centers, no uniformity amongst Dutch head and neck cancer
centers regarding management of the cN0 neck in early stage oral and
oropharyngeal carcinoma. Besides, there was a diﬀerence between
Dutch and German centers concerning the same case examples [53,54].
More recently Govers et al. [55] performed an international comparison
of the management of the neck in early OSCC in the Netherlands, UK,
and USA using questionnaire sent to representatives of head and neck
cancer centers and observed a high variation both within and between
countries [55].
An example of diﬀerences in clinical practice is shown by the ran-
domized clinical trial of the Head and Neck Disease Management group
of Tata Memorial Centre from India on elective versus therapeutic neck
dissection in cN0 oral cancer in patients with lateralized T1 or T2
previously untreated OSCC amenable to undergo transoral excision
[26]. In the observation group in 45% a neck metastasis became ap-
parent, which is much higher than for example in several Dutch studies
using ultrasound guided ﬁne needle aspiration cytology in the pre-
treatment diagnostic work-up (delayed metastasis rate 18–28%)
[31,32,56]. This diﬀerence suggests a less accurate diagnostic work-up
and a diﬀerent target group which may hamper generalizability of their
results. During follow-up all patients in this randomized clinical trial
received physical examination and half of them also had ultra-
sonography. Unfortunately, less than 50% of the patients with a relapse
in the neck were eventually salvaged. Other studies from diﬀerent
countries reported on salvage rates of 75–100% [16,31–33]. In this trial
a 3-years overall survival rate of 68% in the observation group was
found, whereas using a wait and scan follow-up including regular
USgFNAC a 3-year overall survival rate of 90% and a 5-year overall
survival rates of 79%-82% have been reported [16,33]. Moreover, using
their follow-up protocol, 28% of the patients with a relapse in the neck
had metastasis larger than 3 cm (18% larger than 6 cm), 93% extra-
capsular spread and 18% unresectable neck disease. Given the size
distribution of lymph node metastasis detected during surveillance, it is
likely that the follow-up diﬀers from other centers. These data suggest
that there is a substantial diﬀerence in pretreatment work-up and
follow-up between head and neck centers in the world. Since the car-
cinogens (chewed tobacco and areca nut) to which patients in this
randomized clinical trial were exposed, the distribution among subsites
(e.g. buccal mucosa) and their clinical behavior may diﬀer from other
centers over the world [57]. This heterogeneity is a problem to im-
plement study results worldwide [58], even from a successful rando-
mized clinical trial. Nevertheless, this trial clearly shows a prognostic
beneﬁt of END in OSCC in the population in India, where follow-up
without routine USgFNAC is used. Although in this setting END was the
best strategy, this may change after introduction of the SLN biopsy
procedure in the diagnostic work-up [59].
Patient’s preference
For individualized treatment, patients participation is extremely
important. In the decision analysis of Weiss et al. [4] utility (desir-
ability) ratings were generated by consultation with a panel of three
experienced head and neck physicians instead of patients. The authors
clarify that attempts to perform time trade-oﬀ with patients were un-
rewarding, because patients were assumed to have diﬃculty in separ-
ating the morbidity of neck treatment from treatment morbidity in
general [4]. However, physicians may rate morbidity diﬀerent from
patients. Flach et al. [60] performed an evaluation of the patients’
perspective on neck management strategies using semi-structured in-
terviews of early OSCC patients who were treated according a SLN
biopsy strategy with neck dissection in case of a positive SLN. De-
pending on the neck level of the positive SLN and on the preference of
the institute, patients underwent a selective or modiﬁed radical neck
dissection. Twenty-two patients were asked to choose between two
strategies for the neck: an END strategy, which combines staging and
treatment of the neck but which may turn out to be unnecessary, or a
stepwise strategy in which they undergo SLN biopsy to stage the neck
and only in case of a positive SLN biopsy undergo subsequent neck
dissection. In the stepwise SLN biopsy strategy they receive in-
dividualized treatment with the risk of undergoing two operations. Of
these patients, 19 (86%) preferred the SLN biopsy strategy. The 3 (14%)
other patients preferred the END strategy. Of notice, all these 3 patients
were SLN biopsy positive and these 3 patients were 37.5% of all in-
terviewed SLN biopsy positive patients [50]. Therefore, this ﬁnding
may be biased by the fact that all patients had undergone SLN biopsy
and there was no control group in whom patients had undergone END.
Govers et al. [54] calculated health utilities from the EQ-5D-3L ques-
tionnaire outcomes and adjusted for potential confounding by age,
gender and time since treatment. They included four subgroups of cN0
classiﬁed early OSCC patients who underwent diﬀerent diagnostic and
treatment modalities for the neck between 2001 and 2013: watchful
waiting, SLN biopsy, selective neck dissection and modiﬁed radical
neck dissection. The adjusted mean utility scores were 0.804, 0.863,
0.834 and 0.794, respectively [54]. Van der Linden et al. [51] calcu-
lated also health utilities from the EQ-5D questionnaire outcomes in
early OSCC patients treated between 2007 and 2010 and found a score
associated with health status of watchful waiting without regional
failure of 0.84, of watchful waiting with regional failure of 0.79 and of
receiving treatment of the neck of 0.77 [51]. These ﬁgures were dif-
ferent from the study of Weiss et al., in which head and neck physicians
at that time rated utilities of patients in the group of observation
without delayed metastases 1.0, in case of salvaged delayed metastases
0.94 and END 0.97 [4].
Decision aids
Identifying and making a decision on the best treatment can be
diﬃcult for patients. Decision aids can be used when there is more than
one reasonable option, when no option has a clear advantage in terms
of health outcomes, and when each option has beneﬁts and harms that
patients may value diﬀerently. Decision aids describe the options
available and help people to understand these options as well as the
possible beneﬁts and harms. This allows patients to consider the options
from a personal view (e.g. how important the possible beneﬁts and
harms are to them) and prepares them to participate with their health
practitioner in making a decision. The ultimate goal of patient decision
aids is to improve decision making in order to reach a high-quality
decision. Decision aids diﬀer from usual health education materials,
because they make the decision options explicit being considered and
provide a detailed, speciﬁc, and personalized focus on options and
outcomes for the purpose of preparing people for decision making [61].
Patient decision aids supplement (rather than replace) clinicians’
counseling about options. The speciﬁc aims of decision aids and the
type of decision support they provide may vary slightly, but in general
they: (1) provide evidence-based information about a health condition,
the options, associated beneﬁts, harms, probabilities, and scientiﬁc
uncertainties; (2) help patients to recognize the values-sensitive nature
of the decision and to clarify, either implicitly or explicitly, the value
they place on the beneﬁts, harms, and scientiﬁc uncertainties (to ac-
complish this, strategies that may be included in the decision aid are:
describing the options in enough detail that patients can imagine what
it is like to experience the physical, emotional, and social eﬀects; and
guiding patients to consider which beneﬁts and harms are most im-
portant to them); and (3) provide structured guidance in the steps of
decision making and communication of their informed values with
others involved in the decision (e.g. clinician, family, friends) [61]. In a
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Cochrane review, Stacey et al. [61] found that decision aids have a
variable eﬀect on actual choices but they reduce the choice of elective
surgery.
Clinical decision support systems, which link patient data with an
electronic knowledge base in order to improve decision-making, should
be developed in order to individualize the treatment of the cN0 neck in
early OSCC patients based on all relevant data of the patient and out-
come parameters of diagnostics and treatment of the treating center.
However, the development process for patient decision aids is complex
[62].
Comparison between elective neck dissection and other strategies
During the past 25 years selective END of levels I-III has been the
standard approach for the cN0 neck in OSCC. Alternative approaches
have emerged and have been compared with this procedure. However,
comparison is very complex and the above review is to give an over-
view of the dilemmas. A recent systematic review and meta-analysis of
prospective studies on END versus observation in squamous cell carci-
noma of cN0 OSCC patients showed a lower speciﬁc death rate related
to regional recurrences in the END group [63]. A large single center
randomized clinical trial found an improved rate of overall survival for
END as compared to observation [26]. Overall and disease speciﬁc
survival data from large series of SLN biopsy, END and watchful waiting
management in early oral squamous cell carcinoma patients are sum-
marized in Table 2.
Based on the literature up to date, the main strategies are selective
END and SLN biopsy. Head to head comparison in a randomized clinical
trial has not been performed and based on the available literature, the
current debate remains unresolved, in many national guidelines END
and SLN biopsy based strategies are both options in the management of
early stage OSCC. Even if a randomized trial would be performed it
would be the question whether it would provide deﬁnitive and uni-
versally applicable results given the multiple factors that have been
reviewed and discussed above.
Conclusion
In summary, the results of studies on treatment of the cN0 neck
cannot be translated to other settings due to signiﬁcant diﬀerences in
relevant variables such as population, culture, diagnostic work-up,
follow-up, costs and others. Moreover, patients may have personal
preferences and may weigh oncologic outcomes versus morbidity and
quality of life diﬀerently. Given this complexity, we support the con-
clusion of Weiss et al. that “decision analysis is useful in complex
clinical situations.”
In fact much of this has already been acknowledged already in the
1990′s. Weiss et al. [4] in 1994 stated that their analysis may be re-
conﬁgured to determine the optimal management based on a diﬀerent
set of underlying assumptions. Velanovich [5] suggested already in
1990 that each institute needs to review its own survival data and
question patients about quality of life to determine how treatment
options ﬁts into decision analysis and also Davidson et al. [6] stated
that their conclusion is very dependent on whether or not their as-
sumptions and probabilities apply to the particular patient being
managed at any given time. Unfortunately, the 20% risk of occult
lymph node metastasis threshold to perform observation or END, sug-
gested by Weiss et al. [4] in 1994, is still used today by many physicians
and should be adapted to the present time.
Therefore, instead of trying to establish “the” best strategy for the
cN0 neck or “the” optimal cut-oﬀ point for elective neck treatment, the
approach to optimize the management of the cN0 neck would be to
develop and implement models and decision support systems that can
serve to optimize choices depending on individual, institutional, po-
pulation and other relevant variables such as those discussed above.
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